- |||||||||| AD-214 / AdAlta
Trial completion, Enrollment change, Trial completion date, Trial primary completion date: Safety, Tolerability, PK and PD Study of AD-214 Administered to Healthy Volunteers and Patients With Interstitial Lung Disease or Chronic Kidney Disease (clinicaltrials.gov) - Feb 13, 2024
P1, N=8, Completed,
To conclude, i-body AD-214 attenuates UUO-induced kidney fibrosis by inhibiting leukocyte infiltration and macrophage migration. Not yet recruiting --> Completed | N=16 --> 8 | Trial completion date: Jul 2024 --> Feb 2024 | Trial primary completion date: Jul 2024 --> Feb 2024
- |||||||||| AD-214 / AdAlta
Trial completion, Trial completion date, Trial primary completion date: Phase 1 Safety, Tolerability, PK & PD Study of AD-214 Administered to Healthy Volunteers (clinicaltrials.gov) - May 6, 2022
P1, N=50, Completed,
Not yet recruiting --> Completed | N=16 --> 8 | Trial completion date: Jul 2024 --> Feb 2024 | Trial primary completion date: Jul 2024 --> Feb 2024 Active, not recruiting --> Completed | Trial completion date: Jul 2022 --> Feb 2022 | Trial primary completion date: Jul 2022 --> Oct 2021
- |||||||||| AD-214 / AdAlta
Journal: A single domain i-body (AD-114) attenuates renal fibrosis through blockade of CXCR4. (Pubmed Central) - Mar 29, 2022
Additionally, these renoprotective effects were validated in a second model of unilateral ureteral obstruction (UUO) using a second generation of AD-114 (Fc-fused AD-114, also named AD-214). Collectively, these results suggest a renoprotective role of AD-114 as it inhibited the chemotactic function of CXCR4 as well as blocked CXCR4 downstream p38 MAPK and PI3K/AKT/mTOR signaling, which establish a therapeutic strategy for AD-114 targeting CXCR4 to limit renal fibrosis.
- |||||||||| AD-214 / AdAlta
Enrollment closed: Phase 1 Safety, Tolerability, PK & PD Study of AD-214 Administered to Healthy Volunteers (clinicaltrials.gov) - Sep 16, 2021
P1, N=50, Active, not recruiting,
Collectively, these results suggest a renoprotective role of AD-114 as it inhibited the chemotactic function of CXCR4 as well as blocked CXCR4 downstream p38 MAPK and PI3K/AKT/mTOR signaling, which establish a therapeutic strategy for AD-114 targeting CXCR4 to limit renal fibrosis. Recruiting --> Active, not recruiting
|
